Steroid receptor mediated gene activation is crucial for cellular processes involved in cell proliferation, differentiation and development. Transcriptional activation domains in steroid receptors include activation function 1 in the NH2-terminal region and activation function 2 (AF2) in the ligand binding domain. For most steroid receptors, AF2 functions as a binding site for the LXXLL motifs of p160 coactivators. Androgen receptor (AR) AF2 functions primarily as the interaction site for the androgen dependent and specific NH 2- and carboxyl-terminal (N/Q interaction. Two LXXLL-like motifs were identified in the AR NH2-terminal region: FXXLF with sequence 23FQNLF27 and WXXLF with sequence 433WHTLF437, both of which bind AF2 in the presence of androgen. The N/C interaction stabilizes AR by protecting the ligand in the binding pocket and may be required for transactivation in vivo. Inhibition of p160 coactivator recruitment to AF2 by the androgen dependent N/C interaction raises questions regarding the role of AF2 in AR mediated transactivation.
In AIM 1 we will determine the sequence and structural requirements for peptide and protein interactions with AF2. The sequence requirements flanking the FXXLF and LXXLL motifs for binding AF2 will be established. We will determine the crystal structure of the AR ligand binding domain bound to FXXLF and WXXLF peptides and investigate whether the FXXLF or WXXLF motifs serve as binding sites for regulatory proteins or transcription factors. We will investigate the interaction of hsp90 peptides and protein with AF2 and identify peptide inhibitors of AR function.
In AIM 2 we will determine the characteristics of naturally occurring enhancer/promoter elements that require the AR N/C interaction and the role of the N/C interaction in AR mediated transactivation of these androgen regulated genes. Androgen response region spacing sequence, and binding of other factors will be investigated together with the effect of response element DNA on AR conformation and the recruitment of coactivators.
In AIM 3 we will determine the functional importance of the AR N/C interaction by analyzing mice expressing a mutant AR that lacks the N/C interaction. Mice carrying the FXXLF/WXXLF AR mutation will be created by homologous recombination.
In AIM 4 we will characterize the structural arrangement of the AR N/C interaction using electron microscopy of biotinylated purified AR to determine the orientation of the AR dimer bound to androgen response element DNA. We will scale up purification of the androgen-bound full-length baculovirus expressed AR for co-crystallization with androgen response element DNA. The studies will establish the properties and functional importance of the N/C interaction in AR mediated gene activation that could lead to the development of selective therapeutic inhibitors of AR activity.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD016910-23
Application #
6904667
Study Section
Endocrinology Study Section (END)
Program Officer
Rankin, Tracy L
Project Start
1982-08-01
Project End
2009-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
23
Fiscal Year
2005
Total Cost
$383,588
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pediatrics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Tan, Jiann-An; Bai, Suxia; Grossman, Gail et al. (2014) Mechanism of androgen receptor corepression by CK?BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Mol Cell Endocrinol 382:302-313
Su, Shifeng; Minges, John T; Grossman, Gail et al. (2013) Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins. J Biol Chem 288:24809-24
Minges, John T; Su, Shifeng; Grossman, Gail et al. (2013) Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J Biol Chem 288:1939-52
Askew, Emily B; Minges, John T; Hnat, Andrew T et al. (2012) Structural features discriminate androgen receptor N/C terminal and coactivator interactions. Mol Cell Endocrinol 348:403-10
Cherian, Milu T; Wilson, Elizabeth M; Shapiro, David J (2012) A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem 287:23368-80
Titus, Mark A; Zeithaml, Brian; Kantor, Boris et al. (2012) Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One 7:e30192
Su, Shifeng; Blackwelder, Amanda J; Grossman, Gail et al. (2012) Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation. J Biol Chem 287:34809-24
Lagarde, William H; Blackwelder, Amanda J; Minges, John T et al. (2012) Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation. J Biol Chem 287:10905-15
Liu, Qiang; Su, Shifeng; Blackwelder, Amanda J et al. (2011) Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor. J Biol Chem 286:29951-63
Mohler, James L; Titus, Mark A; Bai, Suxia et al. (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71:1486-96

Showing the most recent 10 out of 18 publications